The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance).
 
Christine G Kohn
No Relationships to Disclose
 
Fang-Shu Ou
Consulting or Advisory Role - SC Liver Research Consortium
 
Chao Ma
No Relationships to Disclose
 
Nicholas B Larson
No Relationships to Disclose
 
Tyler J. Zemla
No Relationships to Disclose
 
Chen Yuan
No Relationships to Disclose
 
Donna Niedzwiecki
No Relationships to Disclose
 
Bruce W. Hollis
No Relationships to Disclose
 
Andrew B. Nixon
Consulting or Advisory Role - AdjuVolt; GlaxoSmithKline; Leap Therapeutics; Lilly; Promega
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); medpacto (Inst); OncoMed (Inst); Promega (Inst); Seagen (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Charles David Blanke
No Relationships to Disclose
 
Richard M. Goldberg
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Compass Therapeutics; Eisai/H3 Biomedicine; G1 Therapeutics; GlaxoSmithKline; IQvia; Merck; Sorrento Therapeutics; Taiho Pharmaceutical; UpToDate
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical
 
Robert J. Mayer
Consulting or Advisory Role - Bayer
 
Alan P. Venook
Consulting or Advisory Role - Amgen; BridgeBio Pharma; Exelixis; GlaxoSmithKline; Merck Sharp & Dohme
Research Funding - Amgen
Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Adicet Bio (I); Alnylam (I); AstraZeneca (I); Autem Medical (I); BeiGene (I); Berry Genomics (I); BioSapien; BioSapien; Boehringer Ingelheim; Cend Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai (I); Exelixis (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Helio Health (I); IDEAYA Biosciences; Incyte (I); Ipsen (I); Legend Biotech (I); Merck; Nerviano Medical Sciences (I); Novartis; Noxxon Pharma; QED Therapeutics (I); Rafael Pharmaceuticals; RedHill Biopharma (I); Seagen; Thetis Pharma; Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Celgene (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Parker Institute for Cancer Immunotherapy (Inst); Roche (Inst); Silenseed (Inst)
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Merck
Research Funding - Boston Biomedical (Inst)
 
Kimmie Ng
Honoraria - Bayer
Consulting or Advisory Role - Bicara Therapeutics; BiomX; GlaxoSmithKline; Redesign Health; Seagen; X-Biotix Therapeutics
Research Funding - Evergrande Group (Inst); Janssen (Inst); Pharmavite (Inst); Revolution Medicines (Inst)